Author Archive: Roxan Olivas
C-Path’s Pioneering Neuroscience Workshop Transforms the Landscape of Neurological Disorder Therapies
TUCSON, Ariz., Nov. 9, 2023 – Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled “Transforming Drug Development for Neurological Disorders: Proceedings from a Multi-disease Area Workshop,” now published in Neurotherapeutics, The Journal of the American Society for Experimental Neurotherapeutics.Continue reading
C-Path’s T1D Consortium New-onset Article Published in The Lancet Diabetes and Endocrinology
Research confirms immune-based therapies improve outcomes in new-onset T1DContinue reading
C-Path and CHI Announce Data Sharing Agreement
TUCSON, Ariz., October 26, 2023 — Critical Path Institute (C-Path) and Congenital Hyperinsulinism International (CHI), a leading nonprofit dedicated to improving the lives of children and adults living with Congenital Hyperinsulinism (HI), today announced a data sharing agreement to incorporate rare disease patient-level data from CHI’s HI Global Registry into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading
C-Path Announces Significant Expansion in Neonatal RWD Project
Details of the expansion will be a highlight of the Institute’s Scientific Breakthrough Summit Oct. 26-27 in D.C.Continue reading
C-Path and EATRIS Join Forces with New Collaboration Agreement
AMSTERDAM and TUCSON, Ariz., September 18, 2023 — Critical Path Institute (C-Path) and EATRIS (the European Research Infrastructure for Translational Medicine) are pleased to announce the signing of a collaboration agreement aimed at fostering actionable scientific and educational cooperation. Continue reading
C-Path’s Rare Disease Clinical Outcome Assessment Consortium Launches Rare Disease COA Resource
The Rare Disease COA Resource aims to simplify COA selection for use in rare disease drug development.Continue reading
C-Path Welcomes Sanofi to its Type 1 Diabetes Consortium to Help Advance Drug Development
The global immunology and diabetes leader will collaborate with C-Path’s T1DC to drive transformative change in type 1 diabetes prevention and treatment.Continue reading
C-Path’s Duchenne Regulatory Science Consortium and Duchenne Data Foundation Announce Collaboration to Advance Solutions for Duchenne Muscular Dystrophy
TUCSON, Ariz. and VEENENDAAL, Netherlands, August 9, 2023 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) and the Duchenne Data Foundation (DDF) are excited to announce a joint collaboration aimed at advancing research and improving healthcare for individuals with Duchenne muscular dystrophy (DMD) and other dystrophinopathies (conditions linked to mutations in the DMD gene).Continue reading
The Foundation for Angelman Syndrome Therapeutics to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development
TUCSON, Ariz., July 19, 2023 — Critical Path Institute (C-Path) announced today that the Foundation for Angelman Syndrome Therapeutics (FAST), a nonprofit organization dedicated to finding a cure for this genetic disorder, have contributed data from the Global Angelman Syndrome Registry to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), managed by C-Path.Continue reading